Aflib_8_mg_6_months_intervals_in_EU_ _thumbnail
June 30, 2025

Eylea 8 mg Approved in EU for 6-Month Dosing in nAMD and DME

EU expands Eylea 8 mg label to include longer intervals for nAMD and DME The European Commission (EC) has approved…

Thumbnail Article AMD Barometer Piece (1)
June 11, 2025

Adherence in 2025: How Close Are We to Finally Solving the Retinal Treatment Burden?

“Every time I miss a shot, I see less. But I also might lose my job if I go. What…

latest posts
Aflib_8_mg_6_months_intervals_in_EU_ _thumbnail
June 30, 2025

Eylea 8 mg Approved in EU for 6-Month Dosing in nAMD and DME

Thumbnail Article AMD Barometer Piece (1)
June 11, 2025

Adherence in 2025: How Close Are We to Finally Solving the Retinal Treatment Burden?

SUSVIMO implant
May 23, 2025

FDA Approves Roche’s Susvimo for Diabetic Retinopathy

FDA Rejects Regeneron’s Bid to Extend EYLEA HD Dosing Beyond 16 Weeks
April 22, 2025

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

z4889203089827_b383d19bbac9759a10fd0883c30c5733
November 17, 2023

Geeking Out on Gels and Nanos: Move over, anti-VEGF and lasers! There’s a new cool posterior segment tech in town!

COVER ART TOC
November 17, 2023

A REVOLUTION in Retinal Therapies: From anti-VEGF to TKIs and gene therapy, cutting-edge innovations are changing the landscape of medical retina

img728
October 7, 2023

Going Hybrid: Could combination therapy be the solution for patients with anti-VEGF-resistant AMD?

One out unique pineapple wearing headphones
March 16, 2020

What’s the Buzz on Anti-VEGF Biosimilars?

Discover our fascinating content at issuu

explore